UPMC Hillman Cancer Center | Strategic Alliance Partners

Adam M. Brufsky, MD, PhD, FACP, discusses the use of neratinib and the importance of expanding the treatment portfolio in HER2-positive metastatic breast cancer.

Lan G. Coffman, MD, PhD, assistant professor at the University of Pittsburgh Medical (UPMC) Center Hillman Cancer Center, discusses safety concerns with PARP inhibitors in ovarian cancer.

Michelle M. Boisen, MD, discusses criteria for selecting patients with ovarian cancer for upfront surgery versus neoadjuvant chemotherapy.

Alexander B. Olawaiye, MD, discusses the role of surgery in women with newly diagnosed ovarian cancer.

Adam M. Brufsky, MD, PhD, discusses case ascertainment bias regarding the coronavirus 2019.

Leisha A. Emens, MD, PhD, discusses the incidence and treatment of immune-related adverse events in ovarian cancer.

James M. Rossetti, DO, discusses symptom management for patients with myeloproliferative neoplasms.

John T. Comerci, MD, discusses the utility of primary debulking surgery in ovarian cancer.

James M. Rossetti, DO, discusses symptom management for patients with myeloproliferative neoplasms.

Leisha A. Emens, MD, PhD, discusses the combination of checkpoint inhibitors and PARP inhibitors in ovarian cancer.

Jason J. Luke, MD, FACP, discusses predictive biomarkers in metastatic melanoma.

Jessica Layne Berger, MD, discusses chemotherapy delivery options for patients with ovarian cancer.

Adam M. Brufsky, MD, PhD, FACP, discusses the emergence of biosimilars in oncology and how he anticipates they will change the paradigm.

Sarah E. Taylor, MD, discusses molecular testing recommendations in ovarian cancer.

Michelle M. Boisen, MD, discusses the selection of neoadjuvant chemotherapy versus upfront surgery for women with newly diagnosed ovarian cancer.

Brian Orr, MD, an assistant professor in the Department of Obstetrics, Gynecology & Reproductive Sciences at University of Pittsburgh Medical Center, discusses ongoing biomarker research for immunotherapy in ovarian cancer.

Jessica Layne Berger, MD, discusses the frontline treatment options in newly diagnosed ovarian cancer.

Jason J. Luke, MD, FACP, discusses current and emerging treatment paradigms in metastatic melanoma.

Leisha A. Emens, MD, PhD, discusses a potential future with immunotherapy in ovarian cancer.

Adam M. Brufsky, MD, PhD, discusses the utility of trastuzumab biosimilars in breast cancer.

Robert L. Ferris, MD, PhD, discusses combining STING agonists with checkpoint inhibitors in head and neck cancer.

Antoinette Wozniak, MD, FACP, FASCO, discusses sequencing with immunotherapy and chemoradiation in select patients with stage III lung cancer.

Timothy F. Burns, MD, PhD, discusses methods of identifying genetic alterations in lung cancer.

Liza C. Villaruz, MD, discusses the data with immunotherapy in squamous non–small cell lung cancer.

We traveled to Pittsburgh, Pennsylvania, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from the University of Pittsburgh Medical Center faculty.

Timothy F. Burns, MD, PhD, discusses the frontline standards of care in EGFR-, ALK-, and ROS1-positive non–small cell lung cancer, optimal sequencing strategies, and the nuances of tissue- and plasma-based sequencing.

Antoinette Wozniak, MD, FACP, FASCO, discusses the promise of immunotherapy in lung cancer and shared ongoing research efforts further exploring this approach.

Bernard Fisher, MD, a world-renowned physician/scientist and the chair of the National Surgical Adjuvant Breast and Bowel Project for more than 27 years, has died at the age of 101.

Leisha A. Emens, MD, PhD, discusses the rationale behind the KATE2 study and the results that may signal clinical significance.

Robert L. Redner, MD, a medical oncologist and hematologist, and professor of medicine, at the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, discusses the activity of venetoclax (Venclexta) in acute myeloid leukemia (AML).